EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 75 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... July 20, 2021 Football Player Scores 8 Touchdowns the Day After His Mom Dies... November 17, 2021 EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... March 28, 2025 Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 9, 2020 Load more HOT NEWS Holiday Travel: 11 Things To Know Before Hitting The Road With... Breast cancer surgery: ‘I’m proud of the tattoos inked across my... Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should...
